Bristol Myers Squibb (NYSE: BMY) has announced new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. This data evaluates the efficacy and safety of CAMZYOS® (mavacamten) in adults with New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Bristol Myers Squibb (NYSE: BMY) has released new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study, evaluating CAMZYOS® (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Presented at the European Society of Cardiology (ESC) Congress in London, the data reinforce CAMZYOS’s established efficacy and safety profile.
The results demonstrate that CAMZYOS, a first-in-class cardiac myosin inhibitor, continues to provide significant and sustained improvements in cardiac measures and biomarkers after up to 3.5 years of treatment. Key improvements include reductions in resting and Valsalva left ventricular outflow tract (LVOT) gradients, left atrial volume index, and NT-proBNP levels. Patients also showed enhanced symptoms and functional capacity, with many achieving NYHA class I. The safety profile remained consistent with previous findings, with no new safety concerns reported.
Dr. Pablo García-Pavia from Hospital Universitario Puerta de Hierro emphasized that CAMZYOS addresses a critical need for oHCM patients, offering long-term benefits. Dr. Roland Chen from Bristol Myers Squibb highlighted that CAMZYOS is redefining treatment for symptomatic obstructive HCM, with no new safety signals observed.
The EXPLORER-LTE study included 211 patients, with significant and sustained improvements in echocardiographic measures and biomarkers. The study also demonstrated that CAMZYOS remains effective and safe, making it a key option for managing symptomatic obstructive HCM.
About the EXPLORER-HCM and MAVA-LTE Trials
The EXPLORER-HCM Phase 3 trial (NCT03470545) and the ongoing MAVA-LTE study (NCT03723655) are critical in evaluating CAMZYOS’s long-term effects. The EXPLORER-HCM trial assessed CAMZYOS’s impact on functional endpoints, while MAVA-LTE continues to track the long-term benefits of the therapy in oHCM patients.
About CAMZYOS (mavacamten)
CAMZYOS® (mavacamten) is the first cardiac myosin inhibitor approved in the U.S. for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). It has received global regulatory approvals and is designed to reduce left ventricular outflow tract (LVOT) obstruction and improve cardiac filling pressures by modulating myosin head activity.
